Introduction: Approximately 20-30% of patients with Ulcerative Colitis (UC) require surgery, the majority of these being elective due to chronic symptoms refractory to medical treatment. The decision for surgery is a difficult one and one dependant on patient preferences. Current resources for patients considering surgery have been found not to meet minimum international standards. The overall aim of the 'DISCUSS' study is to develop and evaluate a new Patient Decision Aid (PtDA) for patients considering surgery for UC created in line with international minimum standards.
. Symptoms can be managed using medical therapies such as aminosalicylates, corticosteroids, biologics agents (anti-tumour necrosis factor-α or anti-integrin) and tofacitinib (2) (3) (4) (5) . However approximately 20-30% of patients with UC will require surgery during their disease course (6) . A minority of patients will require emergency surgery -but the majority of patients have elective surgery due to chronic symptoms, refractory to medical treatment (7) . Individuals therefore make a choice, or series of choices, to continue with medical treatment or undergo surgery. Surgery may be undertaken with the intention of proceeding to further reconstructive surgery to restore continuity of the gastrointestinal tract, or remaining with a permanent ileostomy.
The decision to opt for elective surgery is described as preference-sensitive as the preferred treatment option is dependent on patient preferences due to clinical equipoise between the options (8) . The same can be said for the decision between reconstructive surgery versus permanent ileostomy. The impact on lifestyle of these two choices cannot be understatedreconstructive surgery will avoid a stoma, with an acceptance of potential complications such as increased stool frequency, pouchitis or faecal incontinence (9) . A stoma may offer more control over excretory functions, but is associated with complications such as parastomal hernia, as well as psychological sequelae (10, 11) . When selecting a treatment option, it is clear that the patient must select the option based on their preferences. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Shared decision-making is a process whereby clinicians share information about treatment options, empowering the patient to make a decision based on their preferences (12) .
Providing clear and balanced pre-operative information is a major prerequisite to informed decision making (12, 13) . National Institute for Health and Care Excellence (NICE) guidelines for UC emphasise the importance of providing such information, but note that no high quality studies assessing the desired content of information were available on which to base recommendations (14) . As such clinicians lack guidance on patient informational preferences on which to base discussions during consultations. Clinician preferences can be misaligned with patient preferences, especially when considering surgical options for UC (15) , forming a barrier to decision-making in this population. Pre-operative discussions may also be limited by 'implicit persuasion' -a process whereby clinicians subconsciously place greater emphasis on treatment options they believe are suited to the patient (16) . Lack of time in clinic, as well as the lack of guidance on the content of pre-operative consultations, may provide limitations in the shared decision-making process for UC patients (17) .
Patient decision aids
Patient decision aids (PtDAs) are specially created tools which aim to improve patient knowledge and aid decision-making (18, 19) . They are evidenced based, utilising the most upto-date clinical evidence, studies assessing patient informational preferences and evidence on how patients make decisions (20) . PtDAs can be used within the clinical encounter, by the clinician, to provide structure to consultations, but also by the patients outside the encounter to aid their deliberation -a key step to informed consent (13) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 A systematic review of PtDAs in surgery has illustrated their role in improving knowledge, reducing decisional conflict and increasing patient input into decision making (21) . A satisfactory PtDA for patients considering surgery for UC is not currently available. The single aid registered on the Decision Aids Library Inventory (22) does not meet minimum standards laid out by the International Patient Decision Aid Standards (IPDAS) (23) , which have established clear guidance for the systematic development of a PtDA (24) . This can be summarised into 3 stages, as previously described by members of our research group (25) , and forms the methodology behind this protocol. It is therefore proposed that a new PtDA for patients considering surgery for UC, created in-line with minimum standards, will work towards filling an informational need for both patients and clinicians (14, 26) .
Aims and objectives
The aim of this research is to develop, assess and validate a patient decision aid for patients considering elective surgery for ulcerative colitis; i.e. whether to continue with their current medical treatment, or whether to undergo surgery. This will also include information on the different surgical options (mainly permanent stomas vs reconstructive surgery) as this may influence the overall decision to undergo surgery. We will do this in line with the systematic development process specified by IPDAS, ensuring the decision aid meets minimum standards (24, 27) .
The study objectives are to:
1. Develop a decision aid for use by gastroenterology and colorectal surgery teams (consultant surgeons/gastroenterologists, stoma/IBD nurses) to support patients in their decision about elective surgery, and the surgical option they may wish to opt for. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 2. Assess the face validity of the decision aid to support patients make an informed decision about their preferred treatment option.
3. Pilot an evaluation study for the acceptability of the decision aid in clinical practice.
This will use a mixed methods approach to capture the views of:
a. patients making the treatment decision and b. gastroenterology and colorectal surgery health professionals supporting the patient through their decision.
It is anticipated the evaluation of the PtDA will determine whether the administration of a PtDA in the treatment pathway will better support patients in their treatment decisions, as well as providing structure and guidance to consultations with patients.
METHODS AND ANALYSIS
The methodology used for this research has been adapted from a previously published protocol to develop a PtDA for women with cancer to help them make fertility preservation treatment decisions (Cancer, Fertility and Me), led by a member of our research team (GLJ) and funded by Yorkshire Cancer Research (S391) (25) . The protocol also follows established guidance from IPDAS and other recommended guidance regarding the development of PtDA (24, 27) . The study process is summarised in figure 1 .
A steering group with relevant expertise to support PtDA development is essential (24) .
Therefore, a steering group was created prior to protocol development and submission for grant funding to ensure all stakeholders were represented. The steering group consists of; specialist surgical and gastroenterology clinicians, health psychologists with expertise in decision-making, IBD/Stoma nurses, a medical student, and patient representatives. All sections of the protocol have been reviewed and discussed by the steering group. The PtDA 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y will be developed across two regional centres (Sheffield Teaching Hospitals and Hull and East Yorkshire Hospitals). The steering group will hold regular meetings during stage 1 to decide the content and design of the aid, and will hold regular meetings at important stages thereafter. Ethics approval was granted on 13 th March 2019.
Design
Stage 1: Development of the PtDA
Validating patient informational preferences
Our group has already carried out qualitative work exploring patient informational preferences when considering surgery (26) . These results will be validated on a national scale by a questionnaire using established methodology (15, 28) . Questionnaire content will include demographic data, the control preferences scale (29) and questions about the preferred content and format of pre-operative information. This will provide a description of whether particular demographic groups of patients are amenable to a PtDA, and the preferred content and format of such an aid. Questionnaires will be disseminated to a number of sites through an established network of IBD researchers. Prior to questionnaire development, patients will be involved in questionnaire design and refinement via a focus group held at Sheffield Teaching Hospitals. This will help make the findings generalisable and ensure key concepts are included within the questionnaire.
Synthesising the best available evidence
This will consist of the following stages: a) Systematic reviews of evidence about the risks and benefits of elective surgery and continued medical management will be undertaken: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y • A systematic review of outcomes after surgery to inform the PtDA using the best available evidence. Methodology will include the procedures subtotal colectomy with permanent end ileostomy, proctocolectomy, ileal-anal pouch anastomosis and ileorectal anastomosis. Ileorectal anastomosis will be included in the PtDA as our research group notes it is a procedure that is offered in some UK centres, as well as in centres outside the UK. Its inclusion is with the caveat that some centres may not offer this operation, and this will be noted in the aid. Primary outcome will be quality of life, with secondary outcomes covering a wide range of early and late complications after surgery.
• Systematic review of risks and benefits of continued medical treatment. This will inform the decision aid so that the consequences of continued medical treatment -positive and adverse -can be quantified for patients facing this choice.
• Systematic review of the factors that may facilitate or hinder patients with UC to make medical and surgical treatment choices (e.g. possible fear of a stoma)
to ensure these elements are captured and addressed in the new resource. b) Focus groups with expert clinicians, nurses and patients regarding the optimum time to introduce the PtDA into the treatment pathway, as well as the optimum content for each group. This will be via a PPI day at Sheffield Teaching Hospitals.
Drafting the PtDA
Once the evidence has been synthesised, the steering group will meet to decide the content of the aid. The PtDA will be created using IPDAS guidance (24, 27) ; including guidance on balancing options (30), risk presentation (30-33), eliciting patient values (34), use of patient (18) , and enabling readability (35, 36) , something found to be poor in the UC patient literature (23) .
The content of the aid will be guided by the informational preferences studies and systematic reviews of evidence we complete. Significant risks, benefits and outcomes, and their associated probabilities from our reviews will be included. Common topics of informational preferences will be discussed by the group, and a consensus established on the inclusion. The composition of the group, with both expert clinicians and patients, will help to develop content that meets the requirements of both patients and healthcare professionals.
Stage 2: Face validity study
The aim of this stage is to assess the PtDA for comprehension, feasibility and acceptability using key stakeholders -sometimes referred as learner verification or alpha testing (24, 37) .
This will be done with both clinicians and patients, using qualitative methodology, and according to an established protocol, with which we have extensive experience. This will be undertaken across two large sites (Sheffield and Hull).
Sample
A purposive sample of healthcare professionals and patients not involved in the steering group will be invited to take part in the study. The HCP sample will include colorectal surgeons, gastroenterologists, IBD nurses and Stoma nurses. The patient sample will include those who opted for surgery, those who considered but declined surgery and those currently deliberating treatment options. We expect a sample size of 20 participants, with a minimum of 10 healthcare professionals and 10 patients, will be enough based on previous studies and (25) . However, sample size will be guided by data saturation, which is in-line with good qualitative methods (38) (39) (40) .
Recruitment
Ethics will be obtained prior to recruitment. Patients will be identified through the services at the two clinical centres by clinicians and nurses. We will also advertise stage 2 of the study through the Crohn's and Colitis UK forums. Following this the contact details for consenting patients will be passed on to a trained researcher and those willing to participate will be sent the PtDA for review. Healthcare professionals will be recruited from the study sites through purposive sampling. All contact details will be stored securely at either Sheffield Teaching Hospitals or Leeds Beckett University.
Data collection Qualitative
Consenting clinicians and patients will be posted the PtDA and given 1-2 weeks to assess the aid, with a telephone interview taking place at the end of the time period. Patients and clinicians will provide verbal feedback on the aid, focussing on its comprehensibility and ease of use. An interview schedule will be created a priori by expert members of the steering group.
Interviews will be audio recorded, digitalised, and transcribed for analysis.
Quantitative
Patients will also be asked to complete a Preparation for Decision-Making Questionnaire. The Preparation for Decision-Making Questionnaire is a 10-item measure which will provide a score on a scale of 0-100 (41) . The higher the score, the higher the perceived levels of 
Data analysis
Interviews will be transcribed and coded using NVivo 11 Computer-Assisted Qualitative Data Analysis Software (QSR International, Australia). Analysis will use an inductive thematic approach, outlined by Braun and Clarke using a systematic five-step approach: familiarisation, generating initial codes, searching for themes, reviewing themes, and defining and naming themes (40) . The themes actively generated by the researchers from the data will be discussed by the steering group.
The steering group will subsequently refine the aid based on the results of this stage. If there are significant changes required, a second face validity study will be undertaken before progression to stage 3.
Stage 3: Evaluation study
The aim of this pilot is to field test the PtDA in clinical practice, as there may be clinical contextual factors impacting the PtDA. This is typically referred to as beta testing (24) . This will follow a mixed-methods approach across the same two sites as in stage 2. We aim to recruit 15 patients at each site for a minimum sample size of 30 -comparable with other PtDA pilots in the literature (42) . A summary of stage 3 is provided in figure 2 .
Quantitative
Sample and recruitment: All patients over the age of 18 that receive consultation about the possibility of undergoing elective surgery will be included. This includes consultations with clinicians and specialist nurses. We will use the referral model for implementing PtDA -a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 process where the clinician mentions the PtDA to eligible patients during consultation about treatment options, and indicates the clinical researchers will discuss the study following the consultation should the patient consent to involvement (43) . Eligible patients identified by the clinical team will be invited to participate by the researcher(s) with the clinical team immediately following the consultation if they are present, or within a week if the patient consents to contact outside the clinical setting by a member of the research team.
Data measures and collection:
Patients will be asked to complete a series of questionnaires at baseline (1 st clinic appointment) before administration of the PtDA. Patients will be
instructed not to open or view the PtDA before completion of the questionnaires at baseline.
Patients will then complete the same questionnaires at time-point 1 (immediately before the 2 nd clinic appointment). Questionnaires will include a measure of anxiety (STAI-6) (44), Stage of Decision-Making (45) and Decisional Conflict Scale (46) as recommended by IPDAS (24) . All questionnaires will provide a quantitative measure to allow comparison before and after use of the PtDA.
Analysis: Summary statistics will be reported for demographics and other relevant indicators.
For decisional outcome measures we will use paired sample t-tests to calculate mean changes from baseline to time-point 1. Confidence intervals will be set at 95% a priori, meaning values will be significant if p≤0.05.
Qualitative
Sample and recruitment: Healthcare professionals and patients will be asked to take part in semi-structured interviews. We will undertake 10 interviews with patients and 10 with healthcare professionals (IBD/stoma nurses, gastroenterology and surgical clinicians), although this will be guided by data saturation, in line with established protocols in qualitative 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (38, 40) . The interviews will give a deeper insight into the experience of using the aid from a patient and clinician perspective in clinical practice. Clinician interviews will also explore views regarding the timing of the aid in the treatment pathway, establishing if the time previously eliciting in stage 1 is also the optimum time for additional sites. Patients will be recruited using purposive sampling from the sample of 30 that have taken part in the quantitative analysis of stage 3. Prior to interview patients will receive an information sheet, and on the day of interview the patient will be issued a consent form which will be co-signed with the interviewer.
Data collection:
An interview transcript will be created by expert members of the steering group a priori. Questions will be adapted from the transcript used in stage 2, with additional questions to add depth and clarity into the interpretation of the quantitative results.
Questions will also focus on the PtDAs usefulness in helping the patient decide between treatment options.
Analysis: All interviews will be transcribed and coded as per the same methods in stage 2.
Framework analysis, an analysis designed specifically for applied health and policy research (47), will be utilised to identify recurrent themes. Recurrent themes will be discussed with the steering group and subsequent refinement of the PtDA will take place
ETHICS AND DISSEMINATION Ethical considerations
Written, signed consent will be obtained from all participants at stages where it is necessary.
Participants will have the right to withdraw from the research process at any time throughout the study. All interviews will be kept strictly confidential and patients and healthcare 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 professionals will be given a study ID number to maintain this confidentiality. Participation in this study will not interfere with usual patient care.
Dissemination
This a multidisciplinary, collaborative project with clinicians and patients. This will allow us to disseminate the research and its milestones into both the NHS and the wider healthcare community through a variety of local, national and international forums such as charities and international meetings. We will also seek to index an online version of the PtDA in the Decision Aid Library Inventory once we have completed and analysed the paper version. We will also
seek to index the NHS library of decision aids. A web-based version of the PtDA will also allow dissemination through the internet which is widely accessible to patients worldwide. Social media such as twitter and blogs can also be utilised to signpost the availability of the instrument.
We plan to impact the academic and clinical community more widely through a combination of conference presentations and peer-reviewed publications.
The primary output of this study is the PtDA, available in print. This will then be evaluated for effectiveness in a larger study, outside the costings of this grant application. Once fully evaluated it will be promoted more widely through social media, charity websites, professional organisations and academic sources. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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This study is in 3 stages. In stage 1 we will develop the PtDA and its content via systematics reviews and a patient questionnaire. In stage 2 we will assess the face validity of the PtDA using mixed-methods on key stakeholders using both semi-structured interviews and questionnaires, following which the PtDA will be refined. In stage 3 we will assess the acceptability of using the PtDA in clinical practice. This will use a mixed-methods approach on clinicians and patients who are considering undergoing elective surgery. Questionnaires including the Preparation for Decision Making Scale, a measure of anxiety and decisional conflict will be analysed at 2 timepoints using paired sample t-tests and confidence intervals. Interviews with patients and clinicians will be analysed using thematic analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Article summary;
Strengths and limitations of this study:
• This study will develop and evaluate a new patient decision aid for patients considering surgery for ulcerative colitis which will meet minimum international standards. This is a preliminary pilot study.
• This study will provide evidence for its acceptability and value to patients in routine clinical practice when considering surgery for ulcerative colitis.
• This study will also provide evidence of the acceptability of the patient decision aid from the clinicians' perspective and the feasibility of use in routine clinical practice.
• This study will not provide evidence on the value of the PtDA nationally. However, it will provide evidence across two large regional centres in Yorkshire which may be utilised to form the study design of a national evaluation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (1) . Symptoms can be managed using medical therapies such as aminosalicylates, corticosteroids, biologics agents (anti-tumour necrosis factor-α or anti-integrin) and tofacitinib (2) (3) (4) (5) . However approximately 20-30% of patients with UC will require surgery during their disease course (6) . A minority of patients will require emergency surgery -but the majority of patients have elective surgery due to chronic symptoms, refractory to medical treatment (7) . Individuals therefore make a choice, or series of choices, to continue with medical treatment or undergo surgery. Surgery may be undertaken with the intention of proceeding to further reconstructive surgery to restore continuity of the gastrointestinal tract, or remaining with a permanent ileostomy.
Patient decision aids
Patient decision aids (PtDAs) are specially created tools which aim to improve patient knowledge and aid decision-making (18, 19) . They are evidenced based, utilising the most up-to-date clinical evidence, studies assessing patient informational preferences and evidence on how patients make decisions (20) . PtDAs can be used within the clinical encounter, by the clinician, to provide structure to consultations, but also by the patients outside the encounter to aid their deliberation -a key step to informed consent (13) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (24) . This can be summarised into 3 stages, as previously described by members of our research group (25) , and forms the methodology behind this protocol. It is therefore proposed that a new PtDA for patients considering surgery for UC, created in-line with minimum standards, will work towards filling an informational need for both patients and clinicians (14, 26) .
Aims and objectives
The study objectives are to: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 2. Assess the face validity of the decision aid to support patients make an informed decision about their preferred treatment option.
METHODS AND ANALYSIS
Therefore, a steering group was created prior to protocol development and submission for grant funding to ensure all stakeholders were represented. The steering group consists of; specialist surgical and gastroenterology clinicians, health psychologists with expertise in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 decision-making, IBD/Stoma nurses, a medical student, and patient representatives. All sections of the protocol have been reviewed and discussed by the steering group. The PtDA will be developed across two regional centres (Sheffield Teaching Hospitals and Hull and East Yorkshire Hospitals). The steering group will hold regular meetings during stage 1 to decide the content and design of the aid, and will hold regular meetings at important stages thereafter. Ethics approval was granted on 13 th March 2019.
Design
Validating patient informational preferences
Synthesising the best available evidence
This will consist of the following stages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 a) Systematic reviews of evidence about the risks and benefits of elective surgery and continued medical management will be undertaken, as well as a systematic review on factors influencing treatment choices. A full list of inclusion and exclusion criteria for each review is listed in Supplementary appendix (Table S1 , S2, S3):
• A systematic review of outcomes after surgery to inform the PtDA using the best available evidence. This has been registered on the PROSPERO (www.crd.york.ac.uk/PROSPERO) database (ref:
CRD42018115513).Methodology will include the procedures subtotal colectomy with permanent end ileostomy, proctocolectomy, ileal-anal pouch anastomosis and ileorectal anastomosis. Ileorectal anastomosis will be included in the PtDA as our research group notes it is a procedure that is offered in some UK centres, as well as in centres outside the UK. Its inclusion is with the caveat that some centres may not offer this operation, and this will be noted in the aid. Primary outcome will be quality of life, with secondary outcomes covering a wide range of early and late complications after surgery.
• Systematic review of risks and benefits of continued medical treatment. This will inform the decision aid so that the consequences of continued medical treatment -positive and adverse -can be quantified for patients facing this choice. This has been registered on PROSPERO (ref: CRD42019126186).
• Systematic review of the factors that may facilitate or hinder patients with UC to make medical and surgical treatment choices (e.g. possible fear of a stoma) to ensure these elements are captured and addressed in the new resource. This has been registered on PROSPERO (ref: CRD42019125193). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 for each group. This will be via a PPI day at Sheffield Teaching Hospitals.
Drafting the PtDA
Once the evidence has been synthesised, the steering group will meet to decide the content of the aid. The PtDA will be created using IPDAS guidance (24, 27) ; including guidance on balancing options (30), risk presentation (30-33), eliciting patient values (34), use of patient stories (18) , and enabling readability (35, 36) , something found to be poor in the UC patient literature (23) .
The content of the aid will be guided by the informational preferences studies and systematic reviews of evidence we complete. Significant risks, benefits and outcomes, and their associated probabilities from our systematic reviews will be included. Common topics of informational preferences will be discussed by the group, and a consensus established on the inclusion. The composition of the group, with both expert clinicians and patients, will help to develop content that meets the requirements of both patients and healthcare professionals.
Stage 2: Face validity study
This will be done with both clinicians and patients, using qualitative methodology, and according to an established protocol, with which we have extensive experience. This will be undertaken across two large sites (Sheffield and Hull). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Sample
A purposive sample of healthcare professionals and patients not involved in the steering group will be invited to take part in the study. Purposive sampling has been chosen to ensure recruitment of a representative sample of both healthcare professionals and patients. The HCP sample will include colorectal surgeons, gastroenterologists, IBD nurses and Stoma nurses. The patient sample will include those who opted for surgery, those who considered but declined surgery and those currently deliberating treatment options. We expect a sample size of 20 participants, with a minimum of 10 healthcare professionals and 10 patients, will be enough based on previous studies and experience (25) . However, sample size will be guided by data saturation, which is in-line with good qualitative methods (38) (39) (40) .
Recruitment
Patients will be identified through the services at the two clinical centres by clinicians and nurses. We will also advertise stage 2 of the study through the Crohn's and Colitis UK forums. Following this the contact details for consenting patients will be passed on to a trained researcher and those willing to participate will be sent the PtDA for review.
Healthcare professionals will be recruited from the study sites through purposive sampling.
All contact details will be stored securely at either Sheffield Teaching Hospitals or Leeds Beckett University.
Data collection
Qualitative 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Consenting clinicians and patients will be posted the PtDA and given 1-2 weeks to assess the aid, with a telephone interview taking place at the end of the time period. Patients and clinicians will provide verbal feedback on the aid, focussing on its comprehensibility and ease of use. An interview schedule will be created a priori by expert members of the steering group. Interviews will be audio recorded, digitalised, and transcribed for analysis.
Quantitative
Patients will also be asked to complete a Preparation for Decision-Making Questionnaire.
The Preparation for Decision-Making Questionnaire is a 10-item measure which will provide a score on a scale of 0-100 (41) . The higher the score, the higher the perceived levels of preparation for decision-making -which will provide a validated quantitative measure of how individuals view the usefulness of the PtDA (41) .
Data analysis
Interviews will be transcribed and coded using NVivo 11 Computer-Assisted Qualitative Data Analysis Software (QSR International, Australia). Analysis will use an inductive thematic approach, outlined by Braun and Clarke using a systematic five-step approach:
familiarisation, generating initial codes, searching for themes, reviewing themes, and defining and naming themes (40) . The themes actively generated by the researchers from the data will be discussed by the steering group.
The steering group will subsequently refine the aid based on the results of this stage. If there are significant changes required, a second face validity study will be undertaken before progression to stage 3. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The aim of this pilot is to field test the PtDA in clinical practice, as there may be clinical contextual factors impacting the PtDA. This is typically referred to as beta testing (24) . This will follow a mixed-methods approach across the same two sites as in stage 2. We aim to recruit 15 patients at each site for a minimum sample size of 30 -comparable with other
Stage 3: Evaluation study
PtDA pilots in the literature (42) . A summary of stage 3 is provided in figure 2 .
Quantitative
Sample and recruitment: All patients over the age of 18 that receive consultation about the possibility of undergoing elective surgery will be included. This includes consultations with clinicians and specialist nurses. We will use the referral model for implementing PtDA -a process where the clinician mentions the PtDA to eligible patients during consultation about treatment options, and indicates the clinical researchers will discuss the study following the consultation should the patient consent to involvement (43 (24) . All questionnaires will provide a quantitative measure to allow comparison before and after use of the PtDA. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Qualitative
Sample and recruitment: Healthcare professionals and patients will be asked to take part in semi-structured interviews. We will undertake 10 interviews with patients and 10 with healthcare professionals (IBD/stoma nurses, gastroenterology and surgical clinicians), although this will be guided by data saturation, in line with established protocols in qualitative research (38, 40) . The interviews will give a deeper insight into the experience of using the aid from a patient and clinician perspective in clinical practice. Clinician interviews will also explore views regarding the timing of the aid in the treatment pathway, establishing if the time previously eliciting in stage 1 is also the optimum time for additional sites. Patients will be recruited using purposive sampling from the sample of 30 that have taken part in the quantitative analysis of stage 3. Prior to interview patients will receive an information sheet, and on the day of interview the patient will be issued a consent form which will be co-signed with the interviewer.
Data collection: An interview transcript will be created by expert members of the steering group a priori. Questions will be adapted from the transcript used in stage 2, with additional questions to add depth and clarity into the interpretation of the quantitative results.
Questions will also focus on the PtDAs usefulness in helping the patient decide between treatment options. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Analysis: All interviews will be transcribed and coded as per the same methods in stage 2.
Framework analysis, an analysis designed specifically for applied health and policy research (47), will be utilised to identify recurrent themes. Recurrent themes will be discussed with the steering group and subsequent refinement of the PtDA will take place.
Patient and Public Involvement
A patient representative who had prior experience of the decision at question in our PtDA was recruited to the steering committee prior to protocol development. Our representative contributed to overall protocol development, particularly the feasibility of stage 3 to the public. It was anticipated our patient representative would contribute heavily to the design and format of the PtDA, commenting on readability, layout and presentation of information.
Patient representative did not contribute to study recruitment. Patients will also be involved in questionnaire development (stage 1) and design via a focus group. Written, signed consent will be obtained from all participants at stages where it is necessary. Participants will have the right to withdraw from the research process at any time throughout the study. All interviews will be kept strictly confidential and patients and healthcare professionals will be given a study ID number to maintain this confidentiality.
ETHICS AND DISSEMINATION
Participation in this study will not interfere with usual patient care. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This a multidisciplinary, collaborative project with clinicians and patients. This will allow us to disseminate the research and its milestones into both the NHS and the wider healthcare community through a variety of local, national and international forums such as charities and international meetings. We will also seek to index an online version of the PtDA in the Decision Aid Library Inventory once we have completed and analysed the paper version. We will also seek to index the NHS library of decision aids. A web-based version of the PtDA will also allow dissemination through the internet which is widely accessible to patients worldwide. Social media such as twitter and blogs can also be utilised to signpost the availability of the instrument to both clinicians and patients.
Dissemination
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Inclusion Exclusion
Studies which have reported on the facilitators and barriers to ulcerative colitis treatment decision-making for both medical and surgical treatments.
Studies on paediatric patients (defined as under 16 years of age).
Studies using qualitative, quantitative and mixed methods designs.
Studies published in any language other than English. Studies on inflammatory bowel disease patients where the data relating to ulcerative colitis patients is not specified separately.
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